Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan

被引:12
作者
Chang, Po-Yin [1 ]
Lo, Po-Ching [2 ]
Chang, Hui-Chin [2 ]
Hsueh, Kuang-Chieh [3 ]
Tsai, Yi-Wen [2 ]
机构
[1] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[2] Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei, Taiwan
[3] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan
来源
PLOS ONE | 2016年 / 11卷 / 11期
关键词
NICOTINE REPLACEMENT THERAPY; RECEPTOR PARTIAL AGONIST; SUSTAINED-RELEASE BUPROPION; GENDER-DIFFERENCES; SEX-DIFFERENCES; VARENICLINE; POPULATION; SMOKERS; PLACEBO; PATCH;
D O I
10.1371/journal.pone.0166992
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and objective Relative effectiveness of smoking cessation medications-varenicline, bupropion and nicotine replacement therapy (NRT)-remains unclear among smokers in real-world settings. Evidence in females and smokers with light/moderate nicotine dependence is particularly insufficient. This study compared the effectiveness of varenicline, bupropion or NRT gum relative to NRT patch, in achieving abstinence among recent quitters. Methods In a national smoking cessation program in Taiwan (2012-2015), a cohort of 11,968 participants received varenicline (n = 5,052), bupropion (n = 823), NRT gum (n = 1944) or NRT patch (n = 4,149). The 7-day, 1-month or 6-month point-prevalence was calculated based on self-reported last smoking event via telephone interview after 6 months. Logistic regression modellings estimated odds ratios (OR) and 95% confidence intervals (CI) for achieving abstinence using different modalities (NRT patch as referent). Models included age, sex, education, marital status, geographic region, smoke-years, nicotine-dependence level, medical institution, number of clinic visits and medication use duration. Analyses were further stratified by sex and dependence severity. Results Participants were predominantly male (83%) with a mean age of 43.7 +/- 12.6 years. Varenicline users were more likely than NRT patch users to achieve abstinence, based on 7-day point-prevalence (OR = 1.30, CI: 1.19-1.44), 1-month point-prevalence (OR = 1.36, CI: 1.24-1.50) or 6-month point-prevalence (OR = 1.30, CI: 1.14-1.47). Compared with NRT patch, varenicline was associated with greater odds of being abstinent in women (OR = 1.29, CI: 1.01-1.65), men (OR = 1.31, CI: 1.18-1.46), those with light/moderate dependence (OR = 1.42, CI: 1.24-1.63) or smokers with severe dependence (OR = 1.19, CI: 1.04-1.37), based on 7-day point-prevalence. Differences in effectiveness were not observed between users of bupropion, NRT gum and NRT patch. Conclusions In smoking cessation clinics in Taiwan, varenicline users reported higher abstinence rates than NRT patch users after 6 months. Women and smokers with light/moderate nicotine dependence may also benefit from varenicline in actual clinical practice.
引用
收藏
页数:13
相关论文
共 26 条
  • [1] Agaku IT, 2014, MMWR-MORBID MORTAL W, P63
  • [2] Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    Anthenelli, Robert M.
    Benowitz, Neal L.
    West, Robert
    St Aubin, Lisa
    McRae, Thomas
    Lawrence, David
    Ascher, John
    Russ, Cristina
    Krishen, Alok
    Evins, A. Eden
    [J]. LANCET, 2016, 387 (10037) : 2507 - 2520
  • [3] Smoking Cessation Interventions Offered to French Adult Light Smokers: A Heterogeneous Population with Specific Needs
    Baha, Monique Y.
    Le Faou, Anne-Laurence
    [J]. EUROPEAN ADDICTION RESEARCH, 2010, 16 (03) : 162 - 169
  • [4] Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks A Randomized Clinical Trial
    Baker, Timothy B.
    Piper, Megan E.
    Stein, James H.
    Smith, Stevens S.
    Bolt, Daniel M.
    Fraser, David L.
    Fiore, Michael C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (04): : 371 - 379
  • [5] Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006103.pub6, 10.1002/14651858.CD009329.pub2]
  • [6] Pharmacological Treatments for Smoking Cessation
    Cahill, Kate
    Stevens, Sarah
    Lancaster, Tim
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (02): : 193 - 194
  • [7] Determinants of Tobacco Use and Renaming the FTND to the Fagerstrom Test for Cigarette Dependence
    Fagerstrom, Karl
    [J]. NICOTINE & TOBACCO RESEARCH, 2012, 14 (01) : 75 - 78
  • [8] Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
    Gonzales, David
    Rennard, Stephen I.
    Nides, Mitchell
    Oncken, Cheryl
    Azoulay, Salomon
    Billing, Clare B.
    Watsky, Eric J.
    Gong, Jason
    Williams, Kathryn E.
    Reeves, Karen R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 47 - 55
  • [9] A Comparison of the Effectiveness of Varenicline and Transdermal Nicotine Patch in Outpatients Following a Standardized Smoking Cessation Program in Southern Taiwan
    Hsueh, Shu-Chun
    Hsueh, Kuang-Chieh
    Chou, Ming-Yueh
    Tu, Ming-Shium
    [J]. EVALUATION & THE HEALTH PROFESSIONS, 2015, 38 (01) : 115 - 125
  • [10] Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis
    Huang, Yue
    Lewis, Sarah
    Britton, John
    [J]. BMC PUBLIC HEALTH, 2014, 14